Skip to main content
RT @DrTrishHarkins: ❓Vessel wall MRI superior to TA-US in c-GCA❓

🔥In c-GCA vessel wall MRI examines beyond the t

Patricia Harkins DrTrishHarkins

3 years 11 months ago
❓Vessel wall MRI superior to TA-US in c-GCA❓ 🔥In c-GCA vessel wall MRI examines beyond the temporal arteries - ✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures Abst#0473 #ACR22 @RheumNow @RennieRhee https://t.co/ayuPP5v7Lh
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET! #ACR22 https://t.co/BPlVx0rRCd

Dr. John Cush RheumNow

3 years 11 months ago
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET! #ACR22 https://t.co/BPlVx0rRCd
RT @RichardPAConway: Prieto-Pena et al. Tocilizumab in GCA and TAK. Observational study of 70 GCA, 57 TAK in Spain. Simi

Richard Conway RichardPAConway

3 years 11 months ago
Prieto-Pena et al. Tocilizumab in GCA and TAK. Observational study of 70 GCA, 57 TAK in Spain. Similar efficacy in both diseases. @rheumnow #ACR22 Abstr#0465 https://t.co/pyKAILryhH https://t.co/Csp7FIgnzD
RT @synovialjoints: After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition:
◦ more resembled contr

Dr. Antoni Chan synovialjoints

3 years 11 months ago
After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition: ◦ more resembled controls ◦ Enrichment of Collinsella remained stable ◦ Depletion of some species in HLA-B27+ patients from baseline https://t.co/Mw4MToqFcQ Poddubnyy et al @ProftDr #ACR22 @RheumNow
RT @uptoTate: #ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility

Dr. Rachel Tate uptoTate

3 years 11 months ago
#ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility of serum autoantibodies as diagnostic targets for RA subgroups & treatments. This study reminds me of @RheumNow teaching that not all RA created equal. https://t.co/Fjjk6uC0pB https://t.co/Ozr32cJojr
RT @bella_mehta: “It's not that I'm so smart, it's just that I stay with problems longer.” Einstein
Love the quote

Bella Mehta bella_mehta

3 years 11 months ago
“It's not that I'm so smart, it's just that I stay with problems longer.” Einstein Love the quote in the community hub for early career @NIAMSFunding - Perseverance is the KEY in this funding world #ACR22 @RheumNow
RT @RichardPAConway: Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in so

Richard Conway RichardPAConway

3 years 11 months ago
Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in some than comparators. Overall cervical screening, osteoporosis, dyslipidaemia low in this high risk group @rheumnow #ACR22 Abstr#0064 https://t.co/fHQ7ct6yt5 https://t.co/x7gHUDA8zo
RT @RichardPAConway: Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p &l

Richard Conway RichardPAConway

3 years 11 months ago
Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p <0.0001). Highest 1st year - often vasculitis related (35%). After this - infection (28% vs 19%) @rheumnow #ACR22 Abstr#0448 https://t.co/YwwaaB6jDS https://t.co/ogrJkLAd1v
RT @doctorRBC: Good news for patients who require short interruptions in biologic therapy!
Majority of axSpA patients (8

Robert B Chao, MD doctorRBC

3 years 11 months ago
Good news for patients who require short interruptions in biologic therapy! Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease. #Abs0427 @RheumNow #ACR22
RT @RichardPAConway: Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations

Richard Conway RichardPAConway

3 years 11 months ago
Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations in Physical role, Bodily Pain, and PCS. Higher PROMIS pain, lower PROMIS function @rheumnow #ACR22 Abstr#0437 https://t.co/ldC2VEZ0FV https://t.co/0pdjdSZQSS
RT @ericdeinmd: Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22
UPA&gt;ADA from wk 16-56

Eric Dein ericdeinmd

3 years 11 months ago
Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22 UPA>ADA from wk 16-56. UPA and ADA>>PBO Strongly associates with DAPSA or MDA/VLDA composite scores @RheumNow https://t.co/ABY12ar7RS
RT @RichardPAConway: Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relaps

Richard Conway RichardPAConway

3 years 11 months ago
Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relapse OR=0.216. @rheumnow #ACR22 Abstr#0469 https://t.co/sEW1V6NRpb https://t.co/4sAYZbmHX3
RT @uptoTate: Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI &gt; zoster most common) Risks: ische

Dr. Rachel Tate uptoTate

3 years 11 months ago
Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz
RT @RichardPAConway: Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of stero

Richard Conway RichardPAConway

3 years 11 months ago
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
RT @RichardPAConway: Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthrit

Richard Conway RichardPAConway

3 years 11 months ago
Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws
×